Copyright Reports & Markets. All rights reserved.

Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Hepatocellular Carcinoma Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Product
      • 1.4.2 Chemotherapy
      • 1.4.3 Brachytherapy
      • 1.4.4 Ablation Therapy
    • 1.5 Market by End User
      • 1.5.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by End User
      • 1.5.2 Surgical Resection
      • 1.5.3 Liver Transplantation
      • 1.5.4 Ablation
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Hepatocellular Carcinoma Drug Market Size
      • 2.1.1 Global Hepatocellular Carcinoma Drug Revenue 2014-2025
      • 2.1.2 Global Hepatocellular Carcinoma Drug Sales 2014-2025
    • 2.2 Hepatocellular Carcinoma Drug Growth Rate by Regions
      • 2.2.1 Global Hepatocellular Carcinoma Drug Sales by Regions
      • 2.2.2 Global Hepatocellular Carcinoma Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Hepatocellular Carcinoma Drug Sales by Manufacturers
      • 3.1.1 Hepatocellular Carcinoma Drug Sales by Manufacturers
      • 3.1.2 Hepatocellular Carcinoma Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Hepatocellular Carcinoma Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Hepatocellular Carcinoma Drug Revenue by Manufacturers
      • 3.2.1 Hepatocellular Carcinoma Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Hepatocellular Carcinoma Drug Price by Manufacturers
    • 3.4 Hepatocellular Carcinoma Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Hepatocellular Carcinoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Hepatocellular Carcinoma Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Hepatocellular Carcinoma Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Hepatocellular Carcinoma Drug Sales by Product
    • 4.2 Global Hepatocellular Carcinoma Drug Revenue by Product
    • 4.3 Hepatocellular Carcinoma Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Hepatocellular Carcinoma Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Hepatocellular Carcinoma Drug by Countries
      • 6.1.1 North America Hepatocellular Carcinoma Drug Sales by Countries
      • 6.1.2 North America Hepatocellular Carcinoma Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Hepatocellular Carcinoma Drug by Product
    • 6.3 North America Hepatocellular Carcinoma Drug by End User

    7 Europe

    • 7.1 Europe Hepatocellular Carcinoma Drug by Countries
      • 7.1.1 Europe Hepatocellular Carcinoma Drug Sales by Countries
      • 7.1.2 Europe Hepatocellular Carcinoma Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Hepatocellular Carcinoma Drug by Product
    • 7.3 Europe Hepatocellular Carcinoma Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Hepatocellular Carcinoma Drug by Countries
      • 8.1.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Countries
      • 8.1.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Hepatocellular Carcinoma Drug by Product
    • 8.3 Asia Pacific Hepatocellular Carcinoma Drug by End User

    9 Central & South America

    • 9.1 Central & South America Hepatocellular Carcinoma Drug by Countries
      • 9.1.1 Central & South America Hepatocellular Carcinoma Drug Sales by Countries
      • 9.1.2 Central & South America Hepatocellular Carcinoma Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Hepatocellular Carcinoma Drug by Product
    • 9.3 Central & South America Hepatocellular Carcinoma Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Hepatocellular Carcinoma Drug by Countries
      • 10.1.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Countries
      • 10.1.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Hepatocellular Carcinoma Drug by Product
    • 10.3 Middle East and Africa Hepatocellular Carcinoma Drug by End User

    11 Company Profiles

    • 11.1 Johnson & Johnson
      • 11.1.1 Johnson & Johnson Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Johnson & Johnson Hepatocellular Carcinoma Drug Products Offered
      • 11.1.5 Johnson & Johnson Recent Development
    • 11.2 Gilead Sciences
      • 11.2.1 Gilead Sciences Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Gilead Sciences Hepatocellular Carcinoma Drug Products Offered
      • 11.2.5 Gilead Sciences Recent Development
    • 11.3 Pacira
      • 11.3.1 Pacira Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Pacira Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Pacira Hepatocellular Carcinoma Drug Products Offered
      • 11.3.5 Pacira Recent Development
    • 11.4 Sun Pharmaceutical
      • 11.4.1 Sun Pharmaceutical Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Products Offered
      • 11.4.5 Sun Pharmaceutical Recent Development
    • 11.5 Luye Pharma
      • 11.5.1 Luye Pharma Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Luye Pharma Hepatocellular Carcinoma Drug Products Offered
      • 11.5.5 Luye Pharma Recent Development
    • 11.6 Sigma-Tau Group
      • 11.6.1 Sigma-Tau Group Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Products Offered
      • 11.6.5 Sigma-Tau Group Recent Development
    • 11.7 Fudan-Zhangjiang
      • 11.7.1 Fudan-Zhangjiang Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Products Offered
      • 11.7.5 Fudan-Zhangjiang Recent Development
    • 11.8 Teva Pharmaceutical
      • 11.8.1 Teva Pharmaceutical Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Products Offered
      • 11.8.5 Teva Pharmaceutical Recent Development
    • 11.9 CSPC
      • 11.9.1 CSPC Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 CSPC Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 CSPC Hepatocellular Carcinoma Drug Products Offered
      • 11.9.5 CSPC Recent Development
    • 11.10 Novartis
      • 11.10.1 Novartis Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Novartis Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Novartis Hepatocellular Carcinoma Drug Products Offered
      • 11.10.5 Novartis Recent Development
    • 11.11 Kingond Pharm

    12 Future Forecast

    • 12.1 Hepatocellular Carcinoma Drug Market Forecast by Regions
      • 12.1.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Hepatocellular Carcinoma Drug Market Forecast by Product
      • 12.2.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Product 2019-2025
    • 12.3 Hepatocellular Carcinoma Drug Market Forecast by End User
    • 12.4 North America Hepatocellular Carcinoma Drug Forecast
    • 12.5 Europe Hepatocellular Carcinoma Drug Forecast
    • 12.6 Asia Pacific Hepatocellular Carcinoma Drug Forecast
    • 12.7 Central & South America Hepatocellular Carcinoma Drug Forecast
    • 12.8 Middle East and Africa Hepatocellular Carcinoma Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Hepatocellular Carcinoma Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.
      The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
      This report analyzes the worldwide markets for Hepatocellular Carcinoma Drug in US$ by following Product Segments.: Chemotherapy, Brachytherapy and Ablation Therapy.
      Company profiles are primarily based on public domain information including company
      Johnson & Johnson
      Gilead Sciences
      Pacira
      Sun Pharmaceutical
      Luye Pharma
      Sigma-Tau Group
      Fudan-Zhangjiang
      Teva Pharmaceutical
      CSPC
      Novartis
      Kingond Pharm

      The global Hepatocellular Carcinoma Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hepatocellular Carcinoma Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Hepatocellular Carcinoma Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hepatocellular Carcinoma Drug in these regions.
      This research report categorizes the global Hepatocellular Carcinoma Drug market by top players/brands, region, type and end user. This report also studies the global Hepatocellular Carcinoma Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Johnson & Johnson
      Gilead Sciences
      Pacira
      Sun Pharmaceutical
      Luye Pharma
      Sigma-Tau Group
      Fudan-Zhangjiang
      Teva Pharmaceutical
      CSPC
      Novartis
      Kingond Pharm

      Market size by Product
      Chemotherapy
      Brachytherapy
      Ablation Therapy
      Market size by End User
      Surgical Resection
      Liver Transplantation
      Ablation

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Hepatocellular Carcinoma Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Hepatocellular Carcinoma Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Hepatocellular Carcinoma Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Hepatocellular Carcinoma Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Hepatocellular Carcinoma Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hepatocellular Carcinoma Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now